Med-tech firms raising money in public or private financings, including: Mindmaze, Synthego, Turn Medical, Tympa Health.

Biopharmas raising money in public or private financings, including: Sunshine.

Med-tech firms raising money in public or private financings, including: Epitel, Grand Pharmaceutical, ITM, Twist Bioscience.

LONDON – In the largest-ever series A for a Spanish biotech, Splicebio S.L. has raised €50 million (US$56.9 million) to apply its protein splicing technology to the delivery of large genes that do not fit into existing vectors. The company claims its approach will overcome the capacity constraints of adeno-associated viral vectors (AAVs), by splitting genes into parcels and reconstituting the proteins they express in vivo.

Star Therapeutics Inc. emerged from stealth mode to tell the world about its approach to drug discovery and development in rare diseases, and to spin out Electra Therapeutics Inc., the first in a projected family of companies.

Biopharmas raising money in public or private financings, including: Aelis, Centauri, Delos, Egret, Enveric, Fascinate, Grand, ITM, Memo, Nova Mentis, Oncoresponse, Projenx, TC Biopharm.

Biopharmas in Asia-Pacific raising money in public or private financings: Bugworks Research, Ethris, Linkinvax, Merck, Statera, TC, Teclison, Ucello.

Med-tech firms raising money in public or private financings, including: Companion Spine, Memora, Newton Biocapital, Oxdx.

Kallyope Inc., a company leveraging connections between the gut and brain to develop new medicines for diabetes, obesity and other diseases, has raised $236 million in series D financing to support its work. Readouts of early clinical data for its most advanced programs, phase I small molecules for metabolic disease and gut barrier conditions, will start to arrive later this year, company CEO and President Jay Galeota told BioWorld.